Ana Martinez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3692130/publications.pdf

Version: 2024-02-01

316 papers	11,832 citations	26610 56 h-index	43868 91 g-index

342 all docs	342 docs citations	342 times ranked	12915 citing authors

#	Article	IF	Citations
1	Kinase Inhibitors as Underexplored Antiviral Agents. Journal of Medicinal Chemistry, 2022, 65, 935-954.	2.9	30
2	GSK3 Inhibitor-Induced Dentinogenesis Using a Hydrogel. Journal of Dental Research, 2022, 101, 46-53.	2.5	11
3	Targeting autophagy in disease: established and new strategies. Autophagy, 2022, 18, 473-495.	4.3	77
4	Glycogen Synthase Kinase-3 Maleimide Inhibitors As Potential PET-Tracers for Imaging Alzheimerâ€™s Disease: ¹¹C-Synthesis and In Vivo Proof of Concept. Journal of Medicinal Chemistry, 2022, 65, 1342-1351.	2.9	6
5	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry, 2022, 65, 1585-1607.	2.9	20
6	Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2022, 65, 1867-1882.	2.9	11
7	TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimerâ€™s Disease Patients. Biomedicines, 2022, 10, 385.	1.4	3
8	Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades. Journal of Medicinal Chemistry, 2022, 65, 4727-4751.	2.9	10
9	Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3. Biomedicines, 2022, 10, 1136.	1.4	4
10	Glycosylation of Epigallocatechin Gallate by Engineered Glycoside Hydrolases from Talaromyces amestolkiae: Potential Antiproliferative and Neuroprotective Effect of These Molecules. Antioxidants, 2022, 11, 1325.	2.2	5
11	Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDPâ€43â€related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Journal of Neurochemistry, 2021, 156, 379-390.	2.1	20
12	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 2021, 178, 1316-1335.	2.7	28
13	Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 2021, 210, 112968.	2.6	26
14	Mitophagy Modulation, a New Player in the Race against ALS. International Journal of Molecular Sciences, 2021, 22, 740.	1.8	25
15	Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. Pharmaceutics, 2021, 13, 180.	2.0	10
16	Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3Î². Journal of Medicinal Chemistry, 2021, 64, 1497-1509.	2.9	9
17	Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Research, 2021, 186, 105011.	1.9	15
18	Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography. International Journal of Molecular Sciences, 2021, 22, 2440.	1.8	4

#	Article	IF	Citations
19	Molecular Alterations in Sporadic and SOD1-ALS Immortalized Lymphocytes: Towards a Personalized Therapy. International Journal of Molecular Sciences, 2021, 22, 3007.	1.8	16
20	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. International Journal of Molecular Sciences, 2021, 22, 3206.	1.8	15
21	In vitro biological activity of Salvia fruticosa Mill. infusion against amyloid Î²-peptide-induced toxicity and inhibition of GSK-3Î², CK-1Î´, and BACE-1 enzymes relevant to Alzheimer's disease. Saudi Pharmaceutical Journal, 2021, 29, 236-243.	1.2	8
22	Developing novel classes of protein kinase CK1Î´ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. European Journal of Medicinal Chemistry, 2021, 216, 113331.	2.6	9
23	Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?. Expert Opinion on Drug Discovery, 2021, 16, 1-3.	2.5	25
24	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. Pharmaceuticals, 2021, 14, 332.	1.7	21
25	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie, 2021, 133, 19493-19503.	1.6	2
26	Allosteric Modulation of GSK-3Î² as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. International Journal of Molecular Sciences, 2021, 22, 7367.	1.8	5
27	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie - International Edition, 2021, 60, 19344-19354.	7.2	9
28	Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3Î² as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 8975.	1.8	24
29	Small molecule inhibitors of mammalian GSK-3Î² promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species. Journal of Experimental Botany, 2021, 72, 7808-7825.	2.4	4
30	Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Research, 2021, 194, 105167.	1.9	19
31	Phenotypic Assay Leads to Discovery of Mitophagy Inducers with Therapeutic Potential for Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 4512-4523.	1.7	7
32	From simple quinoxalines to potent oxazolo[5,4-f]quinoxaline inhibitors of glycogen-synthase kinase 3 (GSK3). Organic and Biomolecular Chemistry, 2020, 18, 154-162.	1.5	10
33	Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. Journal of Medicinal Chemistry, 2020, 63, 2638-2655.	2.9	10
34	Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 199-210.	2.5	12
35	Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. Neurobiology of Aging, 2020, 96, 148-154.	1.5	6
36	Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3Î² Inhibitor/Nrf2 Inducer for the Treatment of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2020, 11, 2728-2740.	1.7	28

#	Article	IF	Citations
37	Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their in vitro and in silico biological activity connected to Alzheimerâ€™s disease. Bioorganic Chemistry, 2020, 100, 103928.	2.0	9
38	COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry, 2020, 63, 12359-12386.	2.9	348
39	Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1Î´ kinase inhibitor treatment. Scientific Reports, 2020, 10, 4449.	1.6	44
40	Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseases. Expert Opinion on Therapeutic Targets, 2020, 24, 231-243.	1.5	14
41	Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 511-523.	2.5	2
42	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. European Journal of Medicinal Chemistry, 2020, 190, 112090.	2.6	15
43	QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinsonâ€™s Disease Using Cheminformatics Approaches. Advances in Intelligent Systems and Computing, 2019, , 63-70.	0.5	3
44	Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. Molecular Neurobiology, 2019, 56, 2424-2432.	1.9	23
45	Correction of Glycogen Synthase Kinase 3Î² in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice. Molecular and Cellular Biology, 2019, 39, .	1.1	26
46	Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis. Future Medicinal Chemistry, 2019, 11, 1703-1720.	1.1	8
47	Potential anti-Alzheimer effects of selected Lamiaceae plants through polypharmacology on glycogen synthase kinase-3Î², Î²-secretase, and casein kinase 1Î´. Industrial Crops and Products, 2019, 138, 111431.	2.5	24
48	Insights into real-time chemical processes in a calcium sensor protein-directed dynamic library. Nature Communications, 2019, 10, 2798.	5.8	16
49	1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1597-1600.	1.0	9
50	New flavonoid â€“ N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for AlzheimerÂ´s disease endowed with neurogenic properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 712-727.	2.5	27
51	QSAR Modelling to Identify LRRK2 Inhibitors for Parkinsonâ€™s Disease. Journal of Integrative Bioinformatics, 2019, 16, .	1.0	11
52	TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chemical Neuroscience, 2019, 10, 1183-1196.	1.7	37
53	Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases. Processes, 2019, 7, 940.	1.3	7
54	Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy. Autophagy, 2019, 15, 347-351.	4.3	4

#	Article	IF	Citations
55	Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2019, 27, 931-943.	1.4	29
56	Indazolylketones as new multitarget cannabinoid drugs. European Journal of Medicinal Chemistry, 2019, 166, 90-107.	2.6	16
57	Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 87-96.	2.5	10
58	Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. European Journal of Medicinal Chemistry, 2019, 161, 39-47.	2.6	29
59	A Triazolotriazineâ€Based Dual GSKâ€3Î²/CKâ€1Î´ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. ChemMedChem, 2019, 14, 310-314.	1.6	22
60	A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. ACS Chemical Neuroscience, 2019, 10, 279-294.	1.7	18
61	GSK-3 Inhibitors: From theÂBrain to theÂRetina and Back Again. Advances in Experimental Medicine and Biology, 2019, 1185, 437-441.	0.8	6
62	Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis. RSC Drug Discovery Series, 2019, , 170-196.	0.2	0
63	TNFÎ± disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain, Behavior, and Immunity, 2018, 69, 556-567.	2.0	161
64	Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2018, 145, 431-444.	2.6	18
65	Amyloid Î²-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimer's Research and Therapy, 2018, 10, 24.	3.0	64
66	Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Molecular Neurodegeneration, 2018, 13, 19.	4.4	28
67	1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 665-670.	2.5	26
68	Highâ€fructose corn syrup consumption in adolescent rats causes bipolarâ€like behavioural phenotype with hyperexcitability in hippocampal CA3â€CA1 synapses. British Journal of Pharmacology, 2018, 175, 4450-4463.	2.7	12
69	The adiponectin promoter activator NP-1 induces high levels of circulating TNFÎ± and weight loss in obese (fa/fa) Zucker rats. Scientific Reports, 2018, 8, 9858.	1.6	7
70	Tau-Centric Multitarget Approach for Alzheimerâ€™s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3Î² and Tau-Aggregation Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7640-7656.	2.9	81
71	Deciphering the Inhibition of the Neuronal Calcium Sensor 1 and the Guanine Exchange Factor Ric8a with a Small Phenothiazine Molecule for the Rational Generation of Therapeutic Synapse Function Regulators. Journal of Medicinal Chemistry, 2018, 61, 5910-5921.	2.9	10
72	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 156, 534-553.	2.6	38

#	Article	IF	Citations
73	Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
74	Identification of new allosteric sites and modulators of AChE through computational and experimental tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1034-1047.	2.5	33
75	An aminophenothiazine inhibitor of the NCS-1/Ric8a complex regulates synaptic function in fragile X syndrome. Acta Crystallographica Section A: Foundations and Advances, 2018, 74, e38-e39.	0.0	0
76	Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E999-E1008.	3.3	40
77	Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 522-526.	2.5	19
78	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. European Journal of Medicinal Chemistry, 2017, 130, 60-72.	2.6	21
79	Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs, 2017, 26, 403-414.	1.9	22
80	<scp>GSK</scp>â€ɜÎ² inhibitor <scp>TDZD</scp>â€8 reduces neonatal hypoxicâ€ischemic brain injury in mice. CNS Neuroscience and Therapeutics, 2017, 23, 405-415.	1.9	33
81	Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Scientific Reports, 2017, 7, 43545.	1.6	40
82	Inhibition of hippocampal long-term potentiation by high-fat diets. NeuroReport, 2017, 28, 354-359.	0.6	13
83	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinsonâ€™s disease. Future Medicinal Chemistry, 2017, 9, 731-748.	1.1	11
84	Subtly Modulating Glycogen Synthase Kinase 3 Î²: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry, 2017, 60, 4983-5001.	2.9	52
85	A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. Journal of Chemical Neuroanatomy, 2017, 80, 27-36.	1.0	23
86	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology, 2017, 116, 174-187.	2.0	23
87	Biological and Pharmacological Characterization of Benzothiazole-Based CK-1Î´ Inhibitors in Models of Parkinsonâ€™s Disease. ACS Omega, 2017, 2, 5215-5220.	1.6	10
88	Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. Journal of Chemical Information and Modeling, 2017, 57, 2143-2151.	2.5	28
89	3-(Benzyloxy)-1-(5-[¹⁸F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. Future Medicinal Chemistry, 2017, 9, 983-994.	1.1	4
90	Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. European Journal of Medicinal Chemistry, 2017, 138, 328-342.	2.6	24

#	Article	IF	Citations
91	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opinion on Therapeutic Patents, 2017, 27, 657-666.	2.4	40
92	Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. Stem Cells, 2017, 35, 458-472.	1.4	36
93	From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 139, 773-791.	2.6	46
94	Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. Molecules, 2017, 22, 1472.	1.7	6
95	Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. JCI Insight, 2017, 2, e91782.	2.3	22
96	Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs. RSC Drug Discovery Series, 2017, , 153-178.	0.2	2
97	Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors. Molecules, 2016, 21, 193.	1.7	48
98	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. PLoS ONE, 2016, 11, e0162723.	1.1	10
99	Tideglusib, a chemical inhibitor of GSK3Î², attenuates hypoxic-ischemic brain injury in neonatal mice. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 2076-2085.	1.1	40
100	New cinnamic â€“ N-benzylpiperidine and cinnamic â€“ N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. European Journal of Medicinal Chemistry, 2016, 121, 376-386.	2.6	46
101	Development of Bloodâ€“Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. Journal of Medicinal Chemistry, 2016, 59, 7584-7597.	2.9	32
102	Targeting TDP-43 phosphorylation by Casein Kinase-1Î´ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Molecular Neurodegeneration, 2016, 11, 36.	4.4	55
103	New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with Ïƒ-1 agonism and Î²-secretase inhibition. Future Medicinal Chemistry, 2016, 8, 1191-1207.	1.1	23
104	Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain, Behavior, and Immunity, 2016, 53, 207-222.	2.0	132
105	Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets. FÃ¬toterapÃ¬Ã¢, 2016, 109, 241-247.	1.1	33
106	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. European Journal of Medicinal Chemistry, 2016, 116, 281-289.	2.6	10
107	Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3Î² Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 531-544.	2.9	100
108	Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. Current Topics in Medicinal Chemistry, 2016, 16, 3527-3535.	1.0	16

#	Article	IF	Citations
109	<scp>PDE</scp>7 inhibitor <scp>TC</scp>3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. British Journal of Pharmacology, 2015, 172, 4277-4290.	2.7	30
110	Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3. Frontiers in Behavioral Neuroscience, 2015, 9, 55.	1.0	15
111	Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. Neurobiology of Aging, 2015, 36, 1160-1173.	1.5	29
112	Therapeutic approaches for the future treatment of Fragile X. Current Opinion in Behavioral Sciences, 2015, 4, 6-21.	2.0	2
113	Morphometric and neurochemical alterations found in l-BMAA treated rats. Environmental Toxicology and Pharmacology, 2015, 39, 1232-1245.	2.0	22
114	Phosphodiesterase 7 Inhibition Induces Dopaminergic Neurogenesis in Hemiparkinsonian Rats. Stem Cells Translational Medicine, 2015, 4, 564-575.	1.6	38
115	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3Î² Fragment Hits against Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2015, 6, 1665-1682.	1.7	54
116	Analysis of Î²-N-methylamino- l -alanine (L-BMAA) neurotoxicity in rat cerebellum. NeuroToxicology, 2015, 48, 192-205.	1.4	21
117	Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity. RSC Advances, 2015, 5, 15800-15811.	1.7	19
118	Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1,2,3,4-tetrahydro-Î²-carboline (Pinoline) and Melatoninâ€“Pinoline Hybrids. ACS Chemical Neuroscience, 2015, 6, 800-810.	1.7	23
119	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACEâ€1 and GSKâ€3Î² Inhibitors. Angewandte Chemie - International Edition, 2015, 54, 1578-1582.	7.2	107
120	Chapter 9. Heterocycles Containing Nitrogen and Sulfur as Potent Biologically Active Scaffolds. RSC Drug Discovery Series, 2015, , 231-261.	0.2	3
121	From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2015, 22, 3789-3806.	1.2	21
122	Dibenzo[1,4,5]thiadiazepine: A hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases. European Journal of Medicinal Chemistry, 2014, 81, 350-358.	2.6	15
123	Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2014, 57, 2755-2772.	2.9	95
124	Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 73, 56-72.	2.6	43
125	Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8590-8607.	2.9	24
126	cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opinion on Therapeutic Patents, 2014, 24, 1311-1321.	2.4	77

#	Article	IF	Citations
127	New Melatoninâ€“N,N-Dibenzyl(N-methyl)amine Hybrids: Potent Neurogenic Agents with Antioxidant, Cholinergic, and Neuroprotective Properties as Innovative Drugs for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2014, 57, 3773-3785.	2.9	81
128	Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders. ACS Chemical Neuroscience, 2014, 5, 194-204.	1.7	25
129	Glycogen Synthase Kinase-3 Inhibitors Reverse Deficits in Long-term Potentiation and Cognition in Fragile X Mice. Biological Psychiatry, 2014, 75, 198-206.	0.7	101
130	CB1 Blockade Potentiates Down-Regulation of Lipogenic Gene Expression in Perirenal Adipose Tissue in High Carbohydrate Diet-Induced Obesity. PLoS ONE, 2014, 9, e90016.	1.1	15
131	Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinsonâ€™s Disease?. Current Medicinal Chemistry, 2014, 21, 1171-1187.	1.2	23
132	Glycogen Synthase Kinase-3Î² Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. British Journal of Medicine and Medical Research, 2014, 4, 263-271.	0.2	3
133	Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cellular and Molecular Life Sciences, 2013, 70, 3449-3462.	2.4	51
134	Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease.. ACS Chemical Neuroscience, 2013, 4, 350-360.	1.7	69
135	Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin. European Journal of Medicinal Chemistry, 2013, 60, 479-489.	2.6	57
136	Synthesis, Pharmacological Assessment, and Molecular Modeling of Acetylcholinesterase/Butyrylcholinesterase Inhibitors: Effect against Amyloid-Î²-Induced Neurotoxicity. ACS Chemical Neuroscience, 2013, 4, 547-565.	1.7	49
137	Synthesis, pharmacological assessment, and molecular modeling ofÂ6-chloro-pyridonepezils: New dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2013, 67, 64-74.	2.6	30
138	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimerâ€™s and Prion Diseases. ACS Medicinal Chemistry Letters, 2013, 4, 225-229.	1.3	48
139	Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. European Journal of Medicinal Chemistry, 2013, 70, 781-788.	2.6	5
140	Comparative assessment of <scp>PDE</scp> 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 2013, 170, 602-613.	2.7	48
141	Î²-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): The first step towards an experimental model for sporadic ALS. Environmental Toxicology and Pharmacology, 2013, 36, 243-255.	2.0	60
142	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2133-2145.	1.5	77
143	Dual inhibitor of PDE7 and GSK-3 â€“ VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology, 2013, 64, 205-214.	2.0	56
144	Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3. Journal of Immunology, 2013, 190, 5000-5011.	0.4	71

#	Article	IF	Citations
145	Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinsonâ€™s Disease. RSC Drug Discovery Series, 2013, , 294-307.	0.2	5
146	Multitarget Cannabinoids as Novel Strategy for Alzheimer Disease. Current Alzheimer Research, 2013, 10, 229-239.	0.7	17
147	Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease. Current Topics in Medicinal Chemistry, 2013, 13, 1808-1819.	1.0	31
148	Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E817-E830.	1.8	10
149	Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2012, 54, 750-763.	2.6	66
150	Identification in Silico and Experimental Validation of Novel Phosphodiesterase 7 Inhibitors with Efficacy in Experimental Autoimmune Encephalomyelitis Mice. ACS Chemical Neuroscience, 2012, 3, 793-803.	1.7	24
151	Effect of Phosphodiesterase 7 (PDE7) Inhibitors in Experimental Autoimmune Encephalomyelitis Mice. Discovery of a New Chemically Diverse Family of Compounds. Journal of Medicinal Chemistry, 2012, 55, 3274-3284.	2.9	52
152	The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. Journal of Neurochemistry, 2012, 122, 1193-1202.	2.1	15
153	New Tacrineâ€“4-Oxo-4H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimerâ€™s Disease, with Cholinergic, Antioxidant, and Î²-Amyloid-Reducing Properties. Journal of Medicinal Chemistry, 2012, 55, 1303-1317.	2.9	244
154	Benzothiazepine CGP37157 and Its Isosteric 2â€²-Methyl Analogue Provide Neuroprotection and Block Cell Calcium Entry. ACS Chemical Neuroscience, 2012, 3, 519-529.	1.7	26
155	Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: Synthesis, biological assessment, and molecular modeling. European Journal of Medicinal Chemistry, 2012, 57, 296-301.	2.6	53
156	5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2012, 55, 1645-1661.	2.9	76
157	Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo. ACS Chemical Neuroscience, 2012, 3, 963-971.	1.7	139
158	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. European Journal of Medicinal Chemistry, 2012, 47, 175-185.	2.6	64
159	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2012, 48, 206-213.	2.6	27
160	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3Î² (GSK-3Î²) and phosphodiesterase 7 (PDE7) inhibitors: Determination of bloodâ€“brain barrier penetration and binding to human serum albumin. European Journal of Pharmaceutical Sciences, 2012, 45, 677-684.	1.9	30
161	Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. Journal of Medicinal Chemistry, 2011, 54, 8461-8470.	2.9	91
162	Glycogen Synthase Kinase-3. International Journal of Alzheimer's Disease, 2011, 2011, 1-1.	1.1	9

#	Article	IF	Citations
163	Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	1.1	69
164	Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease. PLoS ONE, 2011, 6, e17240.	1.1	83
165	The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy. Current Medicinal Chemistry, 2011, 18, 3028-3034.	1.2	28
166	Reduction of body weight, liver steatosis and expression of stearoylâ€CoA desaturase 1 by the isoflavone daidzein in dietâ€induced obesity. British Journal of Pharmacology, 2011, 164, 1899-1915.	2.7	84
167	Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. Journal of Medicinal Chemistry, 2011, 54, 4042-4056.	2.9	84
168	N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2011, 46, 2224-2235.	2.6	46
169	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Medicinal Research Reviews, 2011, 31, 924-954.	5.0	124
170	An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: The case of a palinurin-related data set of non-ATP competitive Glycogen Synthase Kinase 3Î² (GSK-3Î²) inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 860-869.	2.6	22
171	GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Frontiers in Molecular Neuroscience, 2011, 4, 32.	1.4	274
172	PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. PLoS ONE, 2011, 6, e15937.	1.1	59
173	Chapter 9. Tau Protein Kinases Inhibitors: From the Bench to the Clinical Trials. RSC Drug Discovery Series, 2010, , 173-194.	0.2	1
174	Old phenothiazine and dibenzothiadiazepine derivatives for tomorrowâ€™s neuroprotective therapies against neurodegenerative diseases. European Journal of Medicinal Chemistry, 2010, 45, 6152-6158.	2.6	46
175	Novel Tacrineâ€'8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimerâ€™s Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties. Journal of Medicinal Chemistry, 2010, 53, 4927-4937.	2.9	253
176	Editorial [Hot Topic:Advances in Alzheimer Therapy: Understanding Pharmacological Approaches to the Disease (Guest Editors: Ana Martinez, Debomoy K. Lahiri, Ezio Giacobini and Nigel H. Greig)]. Current Alzheimer Research, 2009, 6, 83-85.	0.7	10
177	NP04634 prevents cell damage caused by calcium overload and mitochondrial disruption in bovine chromaffin cells. European Journal of Pharmacology, 2009, 607, 47-53.	1.7	12
178	Tacrineâ€“Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties. ChemMedChem, 2009, 4, 828-841.	1.6	154
179	Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesteraseâ€...7 Inhibitors. ChemMedChem, 2009, 4, 866-876.	1.6	56
180	Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acidâ€induced seizures in rats. Journal of Neuroscience Research, 2009, 87, 3687-3696.	1.3	15

#	Article	IF	Citations
181	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorganic and Medicinal Chemistry, 2009, 17, 6914-6925.	1.4	49
182	The first enantioselective synthesis of palinurin. Chemical Communications, 2009, , 3252.	2.2	24
183	Neuroprotective and Cholinergic Properties of Multifunctional Glutamic Acid Derivatives for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2009, 52, 7249-7257.	2.9	97
184	Preclinical efficacy on GSKâ€3 inhibitors: Towards a future generation of powerful drugs. Medicinal Research Reviews, 2008, 28, 773-796.	5.0	93
185	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. European Journal of Medicinal Chemistry, 2008, 43, 1349-1359.	2.6	33
186	Non-ATP competitive glycogen synthase kinase 3Î² (GSK-3Î²) inhibitors: Study of structural requirements for thiadiazolidinone derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 495-510.	1.4	57
187	Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2008, 16, 6193-6206.	1.4	20
188	Polyaniline-based microelectrodes for sensing ascorbic acid in beverages. Current Applied Physics, 2008, 8, 320-323.	1.1	38
189	PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opinion on Therapeutic Patents, 2008, 18, 1127-1139.	2.4	42
190	Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1549-1556.	2.5	116
191	Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: Implication of ERK1/2 and PPARÎ³ receptors. Experimental Neurology, 2008, 212, 93-99.	2.0	27
192	Potent Î²-Amyloid Modulators. Neurodegenerative Diseases, 2008, 5, 153-156.	0.8	42
193	GSK-3 Inhibitors: A Ray of Hope for the Treatment of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2008, 15, 181-191.	1.2	119
194	NP031112, a Thiadiazolidinone Compound, Prevents Inflammation and Neurodegeneration under Excitotoxic Conditions: Potential Therapeutic Role in Brain Disorders. Journal of Neuroscience, 2007, 27, 5766-5776.	1.7	108
195	Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structureâ€“Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimerâ€™s Disease. Journal of Natural Products, 2007, 70, 1397-1405.	1.5	123
196	Electron Correlated Ab Initio Study of Amino Group Flexibility for Improvement of Molecular Mechanics Simulations on Nucleic Acid Conformations and Interactions. Journal of Biological Physics, 2007, 33, 499-514.	0.7	2
197	Novel Tacrineâ€'Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties. Journal of Medicinal Chemistry, 2006, 49, 459-462.	2.9	240
198	Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2006, 15, 1-12.	1.9	97

#	Article	IF	Citations
199	Manzamine B and E and Ircinal A Related Alkaloids from an IndonesianAcanthostrongylophoraSponge and Their Activity against Infectious, Tropical Parasitic, and Alzheimer's Diseases. Journal of Natural Products, 2006, 69, 1034-1040.	1.5	129
200	Dual Binding Site Acetylcholinesterase Inhibitors: Potential New Disease-Modifying Agents for AD. Journal of Molecular Neuroscience, 2006, 30, 85-88.	1.1	31
201	Enantioselective LC/MS method for the determination of an antimalarial agent Fenozan B07 in dog plasma. Chirality, 2006, 18, 297-305.	1.3	3
202	Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. Current Pharmaceutical Design, 2006, 12, 4377-4387.	0.9	187
203	Design and synthesis of N-benzylpiperidineâ€“purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorganic and Medicinal Chemistry, 2005, 13, 6795-6802.	1.4	46
204	Donepezilâ€“tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorganic and Medicinal Chemistry, 2005, 13, 6588-6597.	1.4	145
205	Molecular mechanics description of cytosine energy and geometry using preliminary ab initio results. Computational and Theoretical Chemistry, 2005, 729, 59-64.	1.5	3
206	Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1919-1921.	1.0	6
207	SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives:â€‰ Exploration of Structural Requirements for Glycogen Synthase Kinase 3 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7103-7112.	2.9	114
208	Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors. Archiv Der Pharmazie, 2005, 338, 18-23.	2.1	17
209	Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. Medicinal Research Reviews, 2005, 25, 229-244.	5.0	111
210	Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors.. ChemInform, 2005, 36, no.	0.1	0
211	Cyclic Nucleotide Phosphodiesterases and Their Role in Immunomodulatory Responses: Advances in the Development of Specific Phosphodiesterase Inhibitors. ChemInform, 2005, 36, no.	0.1	0
212	Marine compounds for the therapeutic treatment of neurological disorders. Expert Opinion on Therapeutic Patents, 2005, 15, 1377-1386.	2.4	30
213	Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor Î³ Activation. Journal of Biological Chemistry, 2005, 280, 21453-21462.	1.6	174
214	Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors:â€‰ New Disease-Modifying Agents for Alzheimer's Disease. Journal of Medicinal Chemistry, 2005, 48, 7223-7233.	2.9	203
215	GSK-3 Inhibitors: Discoveries and Developments. Current Medicinal Chemistry, 2004, 11, 755-763.	1.2	66
216	CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. QSAR and Combinatorial Science, 2004, 23, 89-98.	1.5	34

#	Article	IF	Citations
217	P4-428 TDZDS: GSK3Î² inhibitors as therapeutic agents for Alzheimer's disease and other tauopathies. Neurobiology of Aging, 2004, 25, S596.	1.5	3
218	Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience, 2004, 128, 73-89.	1.1	68
219	Synthesis and muscarinic activities of O-[(Benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone. Bioorganic and Medicinal Chemistry, 2003, 11, 2263-2268.	1.4	12
220	Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activityâ˜† Bioorganic and Medicinal Chemistry, 2003, 11, 2395-2402.	1.4	5
221	Thienyl and Phenyl Î±-Halomethyl Ketones:â€‰ New Inhibitors of Glycogen Synthase Kinase (GSK-3Î²) from a Library of Compound Searching. Journal of Medicinal Chemistry, 2003, 46, 4631-4633.	2.9	98
222	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents. Expert Opinion on Therapeutic Patents, 2003, 13, 1725-1732.	2.4	15
223	Benzothiadiazine Dioxide Human Cytomegalovirus Inhibitors: Synthesis and Antiviral Evaluation of Main Heterocycle Modified Derivatives. Antiviral Chemistry and Chemotherapy, 2003, 14, 107-114.	0.3	11
224	AMPA Glutamate Receptors and Neuropathic Pain. Mini-Reviews in Medicinal Chemistry, 2003, 3, 757-763.	1.1	4
225	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. Expert Opinion on Therapeutic Patents, 2003, 13, 1725-1732.	2.4	5
226	Preface [Hot topic: Neuropathic Pain: Some Clues for the Future (Executive Editor: Ana Martinez)]. Mini-Reviews in Medicinal Chemistry, 2003, 3, 718-718.	1.1	0
227	First Non-ATP Competitive Glycogen Synthase Kinase 3 Î² (GSK-3Î²) Inhibitors:Â Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2002, 45, 1292-1299.	2.9	421
228	Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?. Expert Opinion on Therapeutic Patents, 2002, 12, 1527-1536.	2.4	49
229	Non-Cholinergic Pharmacotherapy Approaches to the Future Treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2002, 2, 37-50.	1.1	33
230	Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Medicinal Research Reviews, 2002, 22, 373-384.	5.0	302
231	CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. European Journal of Medicinal Chemistry, 2001, 36, 333-338.	2.6	48
232	Recent strategies in the development of new human cytomegalovirus inhibitors. Medicinal Research Reviews, 2001, 21, 227-244.	5.0	27
233	Studies on the reactivity of some Nâ€arylâ€•and Nâ€heteroarylâ€N'â€alkylthioureas towards electrophilic reagents. Synthesis of new Nâ€pyridylthioureas and thiazolines marÃa. Journal of Heterocyclic Chemistry, 2001, 38, 435-441.	1.4	2
234	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.3	6

#	Article	IF	Citations
235	O-Pyrazolylpropynyl-Hydroxylamines as Versatile Intermediates in the Synthesis of Compounds of Pharmacological Interest. Synthesis, 2001, 2001, 1711-1715.	1.2	27
236	Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2001, 1, 267-272.	1.1	134
237	Synthesis of NewN-(4-Pyridyl)-1-aminopyrazoles and Their Muscarinic and Adrenergic Properties. Archiv Der Pharmazie, 2000, 333, 118-122.	2.1	12
238	Reductive Cleavage of Potential Cholinomimetics Thiadiazolidinones: A New Family of Spiro Compounds. European Journal of Organic Chemistry, 2000, 2000, 675-680.	1.2	3
239	Prediction of Drug Half-life Values of Antihistamines Based on the CODES/Neural Network Model. QSAR and Combinatorial Science, 2000, 19, 448-454.	1.4	15
240	Regioselective lipase-catalysed Î³-monoamidation of d-glutamic acid diesters: effect of the N-protecting group. Tetrahedron: Asymmetry, 2000, 11, 2537-2545.	1.8	9
241	Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: N -benzylpiperidine aminoacid derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 731-738.	1.4	11
242	N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2000, 35, 913-922.	2.6	78
243	Hindered Inversion/Rotation in Diheteroaryl Alkyl Amines with a N-(1-Pyrazolyl) Group: Dynamic NMR and Molecular Modelling Studies. Tetrahedron, 2000, 56, 1739-1743.	1.0	12
244	Novel agents for the treatment of human cytomegalovirus infection. Expert Opinion on Therapeutic Patents, 2000, 10, 165-177.	2.4	7
245	Thienothiadiazine 2,2-Dioxide Acyclonucleosides: Synthesis and Antiviral Activity. Antiviral Chemistry and Chemotherapy, 2000, 11, 221-230.	0.3	4
246	Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimerâ€™s disease and other neurodegenerative disorders. Expert Opinion on Therapeutic Patents, 2000, 10, 1519-1527.	2.4	39
247	Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides:â€‰ First Phosphodiesterase 7 Inhibitors. Journal of Medicinal Chemistry, 2000, 43, 683-689.	2.9	74
248	Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Comparative Molecular Field Analysis. Journal of Medicinal Chemistry, 2000, 43, 3218-3225.	2.9	27
249	Nonnucleoside Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Antiviral Evaluation of (Chlorophenylmethyl)benzothiadiazine Dioxide Derivatives. Journal of Medicinal Chemistry, 2000, 43, 3267-3273.	2.9	27
250	Synthesis of New N-(4-Pyridyl)-1-aminopyrazoles and Their Muscarinic and Adrenergic Properties. Archiv Der Pharmazie, 2000, 333, 118-122.	2.1	2
251	Selective dopamine receptors: Synthesis, complexing properties, and molecular modelling studies of new podands derived from 4-hydroxy-1H-pyrazole. Tetrahedron, 1999, 55, 2763-2772.	1.0	20
252	Chlorophenylmethyl benzothiadiazine dioxides derivatives: Potent human cytomegalovirus inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3133-3136.	1.0	10

#	Article	IF	Citations
253	Imidazothiadiazine dioxides: synthesis and antiviral activity. Bioorganic and Medicinal Chemistry, 1999, 7, 1617-1623.	1.4	16
254	On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. Tetrahedron, 1999, 55, 12405-12410.	1.0	12
255	Candida antarctica lipase B catalysed amidation of pyroglutamic acid derivatives. A reaction survey. Journal of Molecular Catalysis B: Enzymatic, 1999, 7, 299-306.	1.8	13
256	Intramolecular oxidative cyclizations in heteroarylthioureas: A versatile pathway to bridgehead heterocyclic systems. Journal of Heterocyclic Chemistry, 1999, 36, 991-995.	1.4	12
257	Synthesis and Potential Muscarinic Receptor Binding and Antioxidant Properties of 3-(Thiadiazolyl)pyridine 1-Oxide Compounds. Archiv Der Pharmazie, 1999, 332, 191-194.	2.1	35
258	Regioselective Lipase-Catalysed Amidation of DicarboxylicN-Blocked Amino Acid Diesters â€“ Effect of the Side-Chain Length. European Journal of Organic Chemistry, 1999, 1999, 2835-2839.	1.2	6
259	Novel Potential Agents for Human Cytomegalovirus Infection:â€‰ Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides. Journal of Medicinal Chemistry, 1999, 42, 1145-1150.	2.9	26
260	Title is missing!. Biotechnology Letters, 1998, 20, 261-263.	1.1	5
261	Enzymatic alcoholysis of SO2-uracil analog diacyclonucleosides. Long-distance effect of the substituents on the regioselectivity. Journal of Molecular Catalysis B: Enzymatic, 1998, 4, 295-302.	1.8	3
262	Synthesis of nonsymmetrically 3,4â€disubstituted 1,2,5â€thiadiazole dioxides. Journal of Heterocyclic Chemistry, 1998, 35, 297-300.	1.4	5
263	Towards lipophilic derivatives of Sâ€adenosylâ€Lâ€methionine. Journal of Heterocyclic Chemistry, 1998, 35, 727-730.	1.4	2
264	Resolution of 1-(4-amino-3-chloro-5-cyanophenyl)-2-bromo-1-ethanol by lipase mediated enantioselective alcoholysis, hydrolysis and acylation. Tetrahedron: Asymmetry, 1998, 9, 2229-2232.	1.8	15
265	Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 505-510.	1.0	58
266	Synthesis and Antiviral Activity of Modified 1,2,6-Thiadiazine Dioxide Acyclonucleosides. Nucleosides & Nucleotides, 1997, 16, 265-276.	0.5	9
267	Regioselective lipase-catalyzed synthesis of l-glutamic Î±-monoamide derivatives. Effect of the N-blocking group. Tetrahedron, 1997, 53, 11745-11752.	1.0	17
268	Selective carriers of norepinephrine and ammonium ions: Ionophoric properties and molecular modelling studies of diester crown compounds containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. Bioorganic and Medicinal Chemistry, 1997, 5, 363-367.	1.4	8
269	Molecular modeling of (E)-1-alkyl-4(3)-[2-(1H-azolyl)vinyl]-pyridinium salts and evaluation of their behavior towards choline acetyltransferase. Bioorganic and Medicinal Chemistry, 1997, 5, 949-954.	1.4	2
270	Comparative Molecular Field Analysis (CoMFA) on [6] + [6] Fused Pyrazines with Nematocide Properties. QSAR and Combinatorial Science, 1997, 16, 372-376.	1.4	3

#	Article	IF	Citations
271	Benzothiadiazine dioxide acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1031-1032.	1.0	14
272	Arylimino-1,2,4-thiadiazolidinones: A new family of potassium channel openers. Bioorganic and Medicinal Chemistry, 1997, 5, 1275-1283.	1.4	19
273	Regioselective lipase catalyzed synthesis of diester crowns. New asymmetric macrocycles containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. Tetrahedron, 1997, 53, 11481-11488.	1.0	6
274	Applications of a statistical model to the analysis of the kinetic parameters in isothermal and non-isothermal crystallization of polymer blends based on PVDF. Polymer, 1997, 38, 2741-2746.	1.8	12
275	Base promoted transformation on thiadiazolopyridinium chlorides. Journal of Heterocyclic Chemistry, 1997, 34, 337-340.	1.4	4
276	Conformation and ortho steric effects in a series of 2â€(pyrazolâ€1â€yl)quinolines. Journal of Heterocyclic Chemistry, 1996, 33, 323-326.	1.4	6
277	New Synthetic Route to of 1,2,4-Thiadiazolines and 1,3-Thiazolines via Thiadiazolopyridinium Salts. Heterocycles, 1996, 43, 2657.	0.4	10
278	Regioselective Mucor miehei lipase catalyzed synthesis of podands containing a 1,3-bis(1H-Pyrazol-1-yl)propane unit. Tetrahedron, 1995, 51, 2417-2426.	1.0	9
279	Dioxides of bicyclic thiadiazines: a new family of smooth muscle relaxants. Bioorganic and Medicinal Chemistry, 1995, 3, 179-185.	1.4	14
280	New 1,2,6-thiadiazine dioxide acyclonucleosides: Synthesis and antiviral evaluation. Bioorganic and Medicinal Chemistry, 1995, 3, 1527-1535.	1.4	16
281	The structure of the compounds resulting from the reaction of arylhydrazines with dehydroacetic acid: an NMR and crystallographic study. Tetrahedron, 1995, 51, 4891-4906.	1.0	18
282	Semiempirical (AM1, PM3 and SAM1) calculations of the protonation enthalpies of proton sponges related to 1,8-diaminonaphthalene. Estimation of the aqueous basicity of new designed superbases. Journal of the Chemical Society Perkin Transactions II, 1995, , 923-927.	0.9	17
283	The Regio- and Stereocontrolled Ring Opening of Heteroarylglycidates with Nitrogen Nucleophiles. Tetrahedron Letters, 1995, 36, 5417-5420.	0.7	9
284	The regio- and stereocontrolled ring opening of heteroarylglycidates with nitrogen nucleophiles. Tetrahedron Letters, 1995, 36, 5417-5420.	0.7	4
285	Regioselective lipase-mediated acylation-deacylation in thiadiazine diacyclonucleosides.. Tetrahedron, 1994, 50, 13865-13870.	1.0	13
286	Tautomerism of benzo- and cyclopenta-[1,2,6]thiadiazine S,S-dioxides. Journal of the Chemical Society Perkin Transactions II, 1994, , 1561-1564.	0.9	13
287	Thiadiazolopyridinium Salts: Intermediates for Heterocyclic Synthesis. Heterocycles, 1994, 38, 1737.	0.4	6
288	The molecular structure of 3(5)-methyl-4,5(3)-trimethylenepyrazole hydrochloride and its13C and15N NMR spectroscopy. Journal of Crystallographic and Spectroscopic Research, 1993, 23, 961-965.	0.3	2

#	Article	IF	Citations
289	Synthesis and biological evaluation of 4-quinolone ribosides. Journal of the Chemical Society Perkin Transactions 1, 1993, , 845.	0.9	15
290	The problem of the existence of C(Ar)â€“H â‹¯ N intramolecular hydrogen bonds in a family of 9-azaphenyl-9H-carbazoles. Journal of the Chemical Society Perkin Transactions II, 1993, , 1547-1555.	0.9	30
291	Application of ultrasonic nebulization for the determination of rare earth elements in phosphates and related sedimentary rocks using inductively coupled plasma atomic emission spectrometry with comments on dissolution procedures. Journal of Analytical Atomic Spectrometry, 1993, 8, 833.	1.6	17
292	SO2 extrusion in 1,2,6-thiadiazine 1,1-dioxides: a novel synthesis of pyrazoles. Canadian Journal of Chemistry, 1993, 71, 410-412.	0.6	14
293	Tautomerism and acidity in 4-quinolone-3-carboxylic acid derivatives. Tetrahedron, 1992, 48, 6135-6150.	1.0	56
294	(E)-1-alkyl-[2-(1H-azol-2-yl)vinyl]pyridinium salts: theoretical analysis, synthesis and evaluation of their interaction with choline acetyltransferase.. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 1493-1496.	1.0	5
295	Lipase-Mediated Acylation of Acyclonucleosides. Application to Novel Fluoroquinolone Derivatives. Synthetic Communications, 1991, 21, 1477-1480.	1.1	14
296	Synthesis of Î·[CH(CN)NH] pseudopeptides. A new peptide bond surrogate. Tetrahedron Letters, 1991, 32, 7579-7582.	0.7	19
297	Synthesis and NMR spectroscopy (¹H ¹³C) of 1â€(2â€²â€benzothiazolyl)â€3(5),4â€polymethylenepyrazoles and related compounds. Journal of Heterocyclic Chemistry, 1991, 28, 647-651.	1.4	13
298	Glycosides of Pyrido [2,3-c]-1,2,6-thiadiazine 2,2-Dioxides. Nucleosides & Nucleotides, 1990, 9, 69-79.	0.5	3
299	A ¹H and ¹³c Nmr study of the structure and tautomerism of 4â€pyrazolylpyrazolinones. Journal of Heterocyclic Chemistry, 1990, 27, 865-870.	1.4	26
300	Structure of 1,2,6-thiadiazine 1,1-dioxides. Journal of Physical Organic Chemistry, 1990, 3, 470-476.	0.9	12
301	Synthesis of a Valuable Precursor for the Preparation of Novel Quinolone Glycosides. Synlett, 1990, 1990, 753-754.	1.0	3
302	Rotational isomerism in 6-Î²-D-glucopyranosides of methyl-1,2,6-thiadiazin-3(2H)-one 1,1-dioxides. Journal of the Chemical Society Perkin Transactions II, 1990, , 783-786.	0.9	9
303	Reaction of 4â€hydrazinoquinolines with Î²â€diketones. Synthesis and spectroscopy (¹h,) Tj ETQq1 1 0.784314 rgBT /O 733-738.	1.4	20
304	On the Tautomerism of 2â€Phenacylâ€4â€pyrimidinones and Related Compounds. Chemische Berichte, 1989, 122, 919-924.	0.2	19
305	Synthesis and Cytostatic Screening of an SO2 Analogue of Doridosine. Archiv Der Pharmazie, 1988, 321, 99-101.	2.1	7
306	Synthesis and spectroscopic properties of Nâ€azolylpropanamides. Journal of Heterocyclic Chemistry, 1988, 25, 225-229.	1.4	17

#	Article	IF	Citations
307	Synthesis of 2S-Dioxo Isosteres of Purine and Pyrimidine Nucleosides IV. Selective Glycosylation of 4-Amino-5H-Imidazo [4, 5-c]-1, 2, 6-Thiadiazine 2, 2-Dioxide. Nucleosides, Nucleotides and Nucleic Acids, 1987, 6, 631-642.	0.4	10
308	N-Glucosyl-5-amino-4-carbamoyl- and 4-Ethoxycarbonylimidazoles as Potential Precursors of 4-Oxoimdazo[4,5-c]-1,2,6-thiadiazine 2,2-Dioxides. Heterocycles, 1986, 24, 3451.	0.4	5
309	Synthesis and intramolecular cyclization of bisthiadiazinylmethane derivatives. Tetrahedron, 1985, 41, 3105-3116.	1.0	11
310	Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments. , 0, , 125-154.		34
311	3-Amino Pyrazoles as Potent and Selective Glycogen Kinase Synthase 3 (GSK-3) Inhibitors. , 0, , 281-305.		4
312	The Crystal Structures of Glycogen Synthase Kinase 3. , 0, , 61-82.		1
313	GSK-3, a Key Player in Alzheimer's Disease. , 0, , 105-124.		0
314	Protein Kinase Assays for Drug Discovery. , 0, , 189-201.		0
315	Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors. , 0, , 307-331.		4
316	TDZD's: Selective and ATP Noncompetitive Glycogen Synthase Kinase 3 Inhibitors. , 0, , 257-280.		2